Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

COVID-19 vaccines helped heart failure patients stay out of the hospital and live longer
Vaccination was linked to key benefits in terms of all-cause mortality, heart failure hospitalizations, stroke, heart attack, myocarditis, venous thromboembolism and testing positive for COVID-19.
New hypertrophic cardiomyopathy guidelines highlight importance of exercise, new drug class
HCM is widely underdiagnosed, but the American College of Cardiology and American Heart Association hope their new guidelines can help cardiologists learn more about the potentially fatal condition and improve patient care.
FDA announces Class I recall after insulin pump software causes 224 injuries
The new recall impacts more than 85,000 devices. If users update their iPhone app as recommended, however, they can continue using the insulin pump as directed.
Cardiologists want better data on how legal marijuana will impact heart health in the US
Many states have legalized the recreational use of marijuana in recent years, creating one of the more radical cultural shifts the United States has seen in quite some time. What could this trend mean from a cardiologist's perspective?
Statin therapy may help HFpEF patients lower their risk of death, heart attack or stroke
All participants were free of ASCVD and had no history of statin use at the start of the study.

Here are links to more details for all of the American College of Cardiology (ACC) late-breaking trial presentations at the ACC.23 meeting March 4-6, in New Orleans. These key late-breaking science sessions include studies in all aspects of cardiovascular medicine, including interventional cardiology, structural heart, cardiac surgery, electrophysiology and drug therapies. Search all the ACC.23 sessions. #ACC23 #ACC #ACClatebreakers

Links to all the American College of Cardiology late-breaking studies for ACC.23

Here are links to more information on every late-breaking presentation at ACC.23.

March 10, 2023

ACC 2023 program chair Douglas Drachman, MD, explains the top takeaways from the American College of Cardiology meeting. #ACC #ACC23

Key takeaways from the ACC 2023 annual meeting

ACC.23 Program Chair Doug Drachman, MD, explains what he saw as some of the key takeaways from the American College of Cardiology (ACC) 2023 annual meeting.

March 10, 2023

Valentin Fuster, MD, PhD, director of Mount Sinai Heart and general director of the Spanish National Center for Cardiovascular Research.

High dosage of blood thinners lowers 30-day morbidity for hospitalized COVID-19 patients

For patients who were hospitalized, but not yet in the ICU, those randomly assigned a higher-dose of anticoagulants had lower 30-day mortality risk than those on a lower dose.

March 10, 2023

Large study finds high rates of nonadherence to statin recommendations; women especially averse

Many patients who would clearly benefit by lowered LDL cholesterol levels are choosing to forgo first-time recommendations for statin regimens, according to a population-level study.

March 3, 2023

Bertram Pitt, MD, a professor of medicine emeritus at the University of Michigan School of Medicine, explains the role of sodium–glucose co-transporter-2 (SGLT-2) inhibitors for heart failure (HF). Initially developed to treat diabetes, these drugs have been shown to improve HF outcomes in HF in several large, randomized trials over the past few years, including SOLOIST-WHF, DAPA-HF, EMPEROR-Preserved, and the DELIVER trials. The positive results earned their inclusion in the 2022 AHA/ACC/HFSA Guideline for

What clinical research tells us about sotagliflozin and heart failure

Some SGLT2 inhibitors have been linked to significant improvements in HF outcomes, but what about sotagliflozin? We spoke with Bertram Pitt, MD, to learn more.

February 21, 2023

Vericiguat consistently linked to positive outcomes, limited side effects among heart failure patients

Reviewing data from several studies, researchers wrote that vericiguat (Verquvo) could potentially "become a breakthrough in the treatment of heart failure."

February 16, 2023

FDA calls out weight loss pills for ‘hidden’ ingredient that puts health of heart patients at risk

The agency’s own analysis confirmed that these capsules contain sibutramine, which was removed from the market back in 2010 due to safety concerns

February 10, 2023

CardiacSense, an Israel-based healthcare technology company, gained FDA clearance for its CSF-3 medical watch

Regulatory Roundup: FDA clears new medical watch, considers empagliflozin for CKD and much more

Our monthly review of FDA-related news items in the world of cardiology includes updates from CardiacSense, MedAlliance, Lupin, Realize Medical and Eli Lilly and Company.

January 31, 2023

Around the web

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business

What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Pharmaceutics

COVID-19 vaccines helped heart failure patients stay out of the hospital and live longer

New hypertrophic cardiomyopathy guidelines highlight importance of exercise, new drug class

FDA announces Class I recall after insulin pump software causes 224 injuries

Cardiologists want better data on how legal marijuana will impact heart health in the US

Statin therapy may help HFpEF patients lower their risk of death, heart attack or stroke

Around the web